Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

• Published in: Clinical cancer research Vol. 14; no. 19; pp. 6330 - 6335
• Main Authors: GEISLER, Jürgen, HELLE, Hilgegunn, EKSE, Dagfinn, DUONG, Nhat K, EVANS, Dean B, NORDBØ, Yngve, AAS, Turid, LØNNING, Per E
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.10.2008
• Subjects: Aged; Aged, 80 and over; anastrozole; Antineoplastic agents; Antineoplastic Agents - therapeutic use; aromatase inhibitors; Biological and medical sciences; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Chromatography, High Pressure Liquid; estradiol; Estradiol - metabolism; Estrogens - blood; estrone; Estrone - analogs & derivatives; Estrone - metabolism; estrone sulfate; Female; Gynecology. Andrology. Obstetrics; Humans; letrozole; Mammary gland diseases; Medical sciences; Middle Aged; Nitriles - therapeutic use; Pharmacology. Drug treatments; Postmenopause; Radioimmunoassay; Triazoles - therapeutic use; Tumors; Antineoplastic agent; Biological fluid; Aromatase inhibitor; Breast disease; Enzyme; Anastrozole; Azole derivatives; Antiestrogen; Estrogen; Enzyme inhibitor; Breast cancer; Antihormone; Estrogen synthase; Malignant tumor; Ovarian hormone; Blood plasma; Mammary gland diseases; Triazole derivatives; Sex steroid hormone; Non steroid compound; Letrozole; Cancer

Purpose: To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E 1 ), estradiol (E 2 ), and estrone sulfate (E 1 S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone r...